Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 plus trastuzumab and XELOX versus trastuzumab and XELOX with or without pembrolizumab in first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
jRCT2041240152Phase 3Recruiting
- Sponsor
- Henlius
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of hlx22 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henlius. Primary endpoints: Progression-free survival and Overall survival. Started Jan 2025; status: recruiting.
02
Drugs
hlx22
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2041240152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240152.